Novocure

Glioblastoma (GBM) Awareness Day is coming up. On #GBMDay and every day, we recognize the impact of GBM, the most common primary brain cancer, on patients and caregivers. Read just a few of their stories: https://lnkd.in/eC5CUYVw

We will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Learn more: https://lnkd.in/esqCy8BB

This June is the first Brain and Spine Metastasis Awareness Month, a reminder to talk about cancers that spread to the brain or spine, often leaving patients with limited treatment options. #MetsGetAwareness

Thank you, Hannah Schmidt, for courageously sharing your story! We are proud to be part of Portsmouth Pride. #pride #NewHampshire #WeAreNovocure

“It’s really about the patients,” says Anne Calixte de Lembeye, who leads our growing business in France. How does the team in France live our patient-forward mission? Enable individuals to take responsibilities. Embrace opportunities, and be perseverant. Today, our thriving team lives not only our mission but also our values of drive and trust. “We need to be proactive and trust people we work with,” Anne says. When Anne joined Novocure in 2020, we were just starting our journey to bring our Tumor Treating Fields (TTFields) therapy to patients in France. She was drawn to Novocure because of our innovative therapy and our patient-forward mission. The team in France grew, adding colleagues in market access and medical, then commercial and patient experience, with the objective to continue clinical development in aggressive solid tumors and support the patients with our patient experience team. To view job opportunities in France and around the globe, visit Novocure.com/careers. #patientforward #TTFields #oncology

The AACR-Novocure Cancer Research Grants provide $350,000 over three years to support independent investigators who are currently conducting innovative research focused on Tumor Treating Fields. Application deadline: July 1. Learn more: https://bit.ly/3VCcJdV

We are excited to share that in May, we opened our new Global Operations Center (GOC) in Baar, Switzerland. “I would like to congratulate all of our colleagues who carefully planned and diligently executed the physical move of our inventory, the installation of the new warehouse infrastructure and many other tasks related to the move of the GOC,” says Jens Hult, Senior Vice President, Global Supply Chain. The GOC is the constantly beating heart of our Global Operations. Its successful upgrade and relocation required close support from our Quality Control, Regulatory, Facilities and other teams as well as external partners. Our new GOC features almost double the amount of available warehouse space of our previous Operations Center in the Root D4 Business park, around 19km (or 11 miles) away from our new location. With an integrated office space, the new facility allows our warehouse, supply chain, quality assurance and service technician teams to engage and collaborate naturally, to bring our therapy equipment quickly and reliably to our patients. Together with our patients, we strive to extend survival in some of the most aggressive forms of cancer, by developing and commercializing our innovative therapy, Tumor Treating Fields (TTFields). The GOC manages intercompany shipments to our other Operation Centers and warehouses around the world. It is a key part of our evolving global supply chain infrastructure, as we expand into new markets, seek approval in new indications and support ongoing clinical trial activities. The new GOC can service larger inbound and outbound shipments, ultimately enabling us to efficiently serve a growing patient population around the world on TTFields therapy.

We are pleased to engage with neuro-oncologists by participating in the Association of French-speaking Neuro-oncologists (#ANOCEF) congress. This is an opportunity to discuss advances in the treatment of patients with brain tumors. Come and chat with us on June 14 and 15! #oncology #glioblastoma #patientforward

In the U.S., we recognize National Black Family Cancer Awareness Week from June 13 through 19. Raising awareness is one way to help move the needle in reducing health disparities. #BlackFamCan #patientforward

We are proud to support the International Brain Tumour Alliance (IBTA) at two medical congresses in Germany in June. At our company booths at the Annual Meeting of the German Society of Neurosurgery (DGNC) and the Annual Congress of the German Society for Radiooncology (DEGRO), we intend to raise support for the IBTA among healthcare professionals. We are challenging individual booth visitors with a quiz and are committed to make a donation to the IBTA that will grow with each correctly answered question. More information on this activity can be found at our booths. Novocure has supported the IBTA’s important work for many years. The IBTA acts as a global network for brain tumour patient and carer groups around the world.